Pharm-Olam is now Allucent. Learn More
Pharm-Olam was contracted to assess a monoclonal antibody (mAb) treatment for Ventilator-Associated Pneumonia (VAP) due to Staphylococcus aureus (S. aureus) in tandem with standard of care (SOC) antibiotic therapy to determine efficacy, safety, and tolerability of proposed treatment. This made the patient targeting complex and narrow, and Pharm-Olam still delivered.
Program Overview: Phase 3
Indication: Multicenter Phase 3 Study Efficacy of mAb Treatment for Ventilator-Associated Pneumonia (VAP) with SOC Antibiotics
Sites & Locations: 160 sites, 20+ countries
Pharm-Olam Services: